Section
PKMYT1 inhibition emerges as a selective and effective therapeutic approach against del(17p) high-risk multiple myeloma by inducing lethal DNA damage and mitotic failure.
The phase 3 SYMPATICO trial demonstrated that first-line combination therapy with ibrutinib and venetoclax yields high complete response rates and durable remissions in patients ≥65 years or with TP53 mutations suffering from nonblastoid ma
A large retrospective study demonstrates that transfusion of low-titer group O whole blood (LTOWB) in trauma resuscitation carries a low and comparable risk of early red blood cell alloimmunization relative to component therapy, including a
This article explores how PD-L1 and PD-L2 differentially regulate immune and lineage-specific programs in primary mediastinal large B-cell lymphoma, providing insights for tailored immunotherapy.
This study identifies neutrophil-dependent type-I interferon responses and NETs as key drivers of joint damage in hemophilia A, opening avenues for novel therapies to prevent hemophilic arthropathy.
Early measurable residual disease (MRD) negativity and timing of relapse are crucial for risk stratification in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with blinatumomab and/or inotuzumab ozogamic
A multicenter retrospective study of 1047 AL amyloidosis patients undergoing autologous stem cell transplantation (2010–2020) demonstrates improved safety, deep hematologic responses, and durable survival, affirming ASCT’s vital role in tre
This review analyzes the impact of age and anthracycline-based chemotherapy on mortality in 28,000 classic Hodgkin lymphoma patients, highlighting poorer outcomes in the elderly and the therapeutic nuances influencing survival.
This phase 2 trial compares CPX-351 with CLAG-M chemotherapy in medically unfit adults with AML, finding CLAG-M achieves better 3-month survival and response rates, especially in patients with proliferative disease, suggesting intensive the
This study identifies systemic pathological pathways that mediate blood-brain barrier injury in sickle cell disease, linking BBB disruption to brain hypoxia and microstructural injury, highlighting new therapeutic targets to preserve neurol
This study reveals that integrin αIIbβ3 deficiency in megakaryocytes disrupts serine metabolism, leading to reduced platelet production and shedding light on the complex pathophysiology underlying Glanzmann thrombasthenia.
Among older adults receiving CAR-T therapy, 5.8% experienced major adverse cardiovascular events (MACE), associated with increased mortality. Pre-existing cardiac conditions heightened risk, underscoring the need for cardiovascular monitori
A retrospective study demonstrates the safety and efficacy of GCSF and plerixafor for CD34+ stem cell mobilization as autologous backup in sickle cell patients undergoing alternate donor HSCT, with insights relevant for gene therapy.
This phase II study evaluates the all-oral ixazomib-pomalidomide-dexamethasone regimen in triple-class exposed relapsed/refractory multiple myeloma patients, demonstrating promising efficacy and manageable safety in an elderly and high-risk
Long-term phase 1 data confirm asciminib’s efficacy and safety in treating CML-CP patients harboring the resistant BCR::ABL1 T315I mutation, with sustained major molecular responses and manageable adverse events over nearly six years.
This article explores how type-I interferon activates NK cells to control polycythemia vera progression, revealing insights into immune modulation and therapeutic potential in myeloproliferative neoplasms.
A phase II trial demonstrates the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning in AML patients aged 40-65, showing high leukemia-free survival and low toxicity, supporting its use over busulfan r
This study reveals early establishment of a diverse naïve B-cell receptor repertoire within 3 months post-pediatric HSCT, followed by gradual antigen-experienced maturation over 24 months, reflecting physiological B-cell development and sup
Bendamustine monotherapy achieved high response rates and inhibited STAT3 signaling in patients with high burden T-cell large granular lymphocytic leukemia, showing promise as an effective and well-tolerated treatment option.
This study develops a high-content ex vivo assay of T cell dynamics to predict multiple myeloma patient response to bispecific T cell engager therapies, offering a novel functional biomarker for therapy stratification.
